Studies bone marrow samples from children with acute leukemia
Collects bone marrow samples from children with acute leukemia and control children.
Plain-language title generated from the registry record
Registry title: Study of the Medullary Microenvironment in Acute Childhood Leukemia
Key facts
- Where
- Tours, FranceSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 15 years old?
Source: NCT05792007, who can take part
Where in France
- Service d'hématologie biologique-CHRU TOURSTours, FranceNot yet recruiting
- Service d'onco-hématologie pédiatrique -CHRU ToursTours, FranceTaking people
- Service de chirurgie orthopédique pédiatrique -CHRU TOURSTours, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Tours
- Trial code
- NCT05792007
- Record updated
- 24 November 2025
- Original description
Acute leukemia (AL) is the most common cancer in children. Despite the optimization of chemotherapy treatments and the development of supportive care, a certain number of LAs relapse and/or progress to death of the child. It therefore seems essential to try to better understand the physiopathology and the mechanisms of resistance to treatment of these diseases.Read full original descriptionShow less
Etude du Microenvironnement médullaire Dans Les Leucémies Aiguës de l'Enfant
Acute leukemia (AL) is the most common cancer in children. Despite the optimization of chemotherapy treatments and the development of supportive care, a certain number of LAs relapse and/or progress to death of the child. It therefore seems essential to try to better understand the physiopathology and the mechanisms of resistance to treatment of these diseases.
Inclusion: for patients with AL:; Child with acute lymphoblastic or myeloblastic leukemia at diagnosis; Not having received prior hematological treatment; Aged 1 to 15 years old; Whose 2 parents, or the holder of parental authority, have signed a consent enlightened; Affiliated patient or beneficiary of a social security scheme; Control group patients:; Child undergoing orthopedic surgery exposing the bone marrow (osteotomy of the pelvis); Aged between 1 and 15 years old; Having no pathology of hematological origin; Not having received any treatment that could interfere with the functioning of the bone marrow; Whose 2 parents or the holder of parental authority have signed a consent enlightened; Affiliated patient or beneficiary of a social security scheme.
Exclusion: for patients with AL:; Patient under 1 year old and over 15 years old; Contraindication to myelogram; Absence of signature of the informed consent by the 2 parents or the holder of parental authority; Patients with relapsed acute lymphoblastic or myeloblastic leukemia; Having received prior hematological treatments; Parents with physical or mental condition not allowing to understand the informed consent; Control group patients; Patient under 1 year old and over 15 years old; Having an underlying haematological pathology; Absence of signature of the informed consent by the 2 parents or the holder of parental authority; Having received prior hematological treatments; Parents with physical or mental condition not allowing to understand informed consent.